iData Insights

High-Grade Glioma - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 29, 2016 16:51 IST

High-Grade Glioma - Pipeline Review, H2 2015 Summary Global Markets Direct s, High-Grade Glioma - Pipeline Review, H2 2015 , provides an overview of the High-Grade Glioma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for High-Grade Glioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the High-Grade Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the High-Grade Glioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 8

Global Markets Direct Report Coverage 8

High-Grade Glioma Overview 9

Therapeutics Development 10

Pipeline Products for High-Grade Glioma - Overview 10

Pipeline Products for High-Grade Glioma - Comparative Analysis 11

High-Grade Glioma - Therapeutics under Development by Companies 12

High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes 14

High-Grade Glioma - Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

High-Grade Glioma - Products under Development by Companies 17

High-Grade Glioma - Products under Investigation by Universities/Institutes 18

High-Grade Glioma - Companies Involved in Therapeutics Development 19

AngioChem Inc. 19

Arog Pharmaceuticals, Inc. 20

Bayer AG 21

Boehringer Ingelheim GmbH 22

Cavion LLC 23

Kinex Pharmaceuticals, LLC 24

Merrimack Pharmaceuticals, Inc. 25

Millennium Pharmaceuticals, Inc. 26

Nektar Therapeutics 27

Novartis AG 28

Oncolytics Biotech Inc. 29

Sanofi 30

Stemline Therapeutics, Inc. 31

Targepeutics, Inc. 32

Tocagen Inc. 33

Virttu Biologics Limited 34

High-Grade Glioma - Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Combination Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

alisertib - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

crenolanib besylate - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Dendritic Cell Therapy for Gliomas - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Dendritic Cell Therapy for Oncology - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

dianhydrogalactitol - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

etirinotecan pegol - Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

flucytosine + TBio-01 - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

GB-13 - Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

HSV-1716 - Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

irinotecan hydrochloride - Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

irinotecan hydrochloride + TBio-02 - Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

KX-02 - Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

mibefradil dihydrochloride - Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

nintedanib - Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

paclitaxel trevatide - Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

pelareorep - Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

plerixafor - Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

SL-701 - Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

sorafenib tosylate - Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

Toca-Gamma - Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Toca-RNAi - Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

vocimagene amiretrorepvec + flucytosine ER - Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

High-Grade Glioma - Recent Pipeline Updates 100

High-Grade Glioma - Dormant Projects 153

High-Grade Glioma - Discontinued Products 154

High-Grade Glioma - Product Development Milestones 155

Featured News & Press Releases 155

Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 155

May 28, 2015: Cavion to Present Clinical Trial Data at ASCO 156

May 31, 2014: Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin?-Refractory High-Grade Glioma Presented at 50th ASCO Meeting 156

Appendix 158

Methodology 158

Coverage 158

Secondary Research 158

Primary Research 158

Expert Panel Validation 158

Contact Us 158

Disclaimer 159

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects